BRUSSELS, Belgium – June 28, 2018 – At the European SLAS 2018 meeting (www.slaseurope2018.org), Bruker today announced the launch of its new SierraTM SPR-32 system with even higher sensitivity and new instrument control software to enable highest SPR throughput with outstanding sensitivity.
Powered by its new touch-compatible R3 software, the Sierra SPR-32 has innovative new features like ‘Frame Inject’ and allows for turn-key sample processing protocols and customized workflows created together with pharmaceutical customers. The faster data analysis and highly intuitive user interface combine to deliver an industry-leading SPR throughput of 10,000 control-substracted binding measurements. Combining flexible 8-needle sample delivery with a 32-sensor detection array laid out in 8 detection flow cells, enables 4 sensors per flow cell, an important advantage for controlled, high-throughput SPR methods. The patented Hydrodynamic Isolation™ technology enables ‘Any Sample, Any Sensor, Any Time’, making it the preferred platform for screening, kinetics, thermodynamics and epitope mapping for pharmaceutical applications.
Christopher Whalen, Bruker Director of Global SPR Sales, said: “The new R3 software with the proprietary non-linear detection algorithm and new data processing engine, makes the Sierra SPR-32 even faster and even more sensitive. Our four-sensor per channel design provides maximum control analysis flexibility, enabling good throughput for even the most complex analyses. Samples can be simultaneously assayed on the active sensor and with up to three controls. In many SPR applications the early analysis of non-specific binding to matrix proteins such as HSA or BSA can be critical. The additional inline control not only halves the number of assay cycles required vs. two sensor flow cells, but it can also improve data quality by eliminating potential variations between multiple sample preparations.”
Dr. Meike Hamester, the Bruker Daltonics Director - Small Molecule Pharma Business, commented: “The complementary nature of label-free detection technologies represented by the new Sierra SPR-32, and Bruker’s NMR and MALDI PharmaPulse™ mass spectrometry solutions for drug discovery can help in the design of efficacious and safer drugs at lower cost. Improving the hit-to-lead identification speed helps, but improving the understanding of the relationship of structure to binding kinetics using liquid phase, label-free techniques, will go a long way in taking new chemical entities to clinical trials faster.”
About Bruker Corporation (NASDAQ: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.